enalapril / Generic mfg. - LARVOL DELTA

Hydrolyzed Collagen from Salmon Skin Mitigates L-NAME-Induced Hypertension in Rats by Attenuating Oxidative Stress and Inflammation and Improving Vascular Remodeling. (PubMed, Int J Mol Sci) - "Hypertension was induced in rats by the oral administration of L-NAME (40 mg/kg/day) for eight weeks, while HC in two doses (50, 450 mg/kg) or enalapril at 10 mg/kg dissolved in water were concurrently administered via oral gavage for the last four weeks...Vascular function was improved, as evidenced by significantly higher relaxation responses to acetylcholine (ACh) in the presence or absence of endothelium. These findings indicate that HC effectively lowered the blood pressure in hypertensive rats, potentially through mechanisms involving the modulation of oxidative stress and the expression of nitric oxide, reducing vascular inflammation and remodeling, hence enhancing vascular function."

Journal • Preclinical • Cardiovascular • Hypertension • Inflammation

C1Q-POSITIVE DE NOVO IGA NEPHROPATHY FOLLOWING COVID-19 INFECTION, CONFIRMED BY GD-IGA1 STAINING AFTER KIDNEY TRANSPLANTATION (ISN-WCN 2026) - "She was maintained on steroids, tacrolimus, azathioprine and everolimus, and serum creatinine remained stable at 1.0-1.2 mg/dL. She contracted COVID-19 and was treated with molnupiravir three months before this visit...Consequently, treatment with enalapril and dapagliflozin was initiated, and steroid dosage was tapered.Results The patient exhibited no risk factors for secondary IgAN, and the diagnosis of IgAN was confirmed through Gd-IgA1 staining...Furthermore, the presence of C1q deposits, which are uncommon and considered indicators of poor renal prognosis in primary IgAN, was noted in this patient. Based on the clinical progression, C1q deposits in de novo IgAN may similarly be associated with adverse renal outcomes.This work was first presented at ASN Kidney Week 2025, and re-submission is permitted by ASN.Conclusion"

ANCA Vasculitis • Fibrosis • Glomerulonephritis • IgA Nephropathy • Immunology • Infectious Disease • Novel Coronavirus Disease • Renal Disease • Respiratory Diseases • Transplantation • Vasculitis

UNDERSTANDING READINESS WITH COM-B: BARRIERS AND ENABLERS FOR HYPERTENSION AND DIABETES SCREENING IN PRIMARY HEALTH CARE IN ADDIS ABABA, ETHIOPIA (ISN-WCN 2026) - "Eight centers had all antihypertensive medications available, while Hydralazine and Enalapril were missing in two.A total of 814 staff were reported across all facilities, including 549 key clinical staff (39 physicians, 319 nurses, 191 health officers). Improving hypertension and diabetes screening and management in Ethiopia requires strengthening workforce capacity, ensuring consistent diagnostic and medication supplies, and implementing supportive staff policies.Given that uncontrolled hypertension and diabetes are the leading precursors of chronic kidney disease, enhancing PHC readiness for early detection and management directly contributes to CKD prevention and better kidney health outcomes. Integrating kidney health indicators within existing NCD programs, expanding access to renal function testing, and fostering interlinkages between hypertension, diabetes, and CKD care at the primary level could significantly reduce the long-term burden of kidney disease in..."

Cardiovascular • Chronic Kidney Disease • Diabetes • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease

A RARE COEXISTENCE OF C3 GLOMERULOPATHY AND SYSTEMIC LUPUS ERYTHEMATOSUS IN A YOUNG FEMALE (ISN-WCN 2026) - "There is no established optimal treatment for C3G, and while newer studies show that eculizumab suggests benefit for both diseases, it was not available locally. Similar to some of the previous reports, our patient was treated with methylprednisolone pulse therapy, hydroxychloroquine, mycophenolate mofetil, and enalapril, which resulted in low disease activity...Enhanced understanding of the pathophysiological mechanisms and continued research are essential for improving patient management and outcomes in these unique cases.Disclaimer: This abstract was also submitted for the Asia-Pacific League of Associations for Rheumatology (APLAR) congress. By submitting the abstract to WCN'26, abstract authors declare that re-submitting the abstract is permitted by the organizers of the previous meeting."

Complement-mediated Rare Disorders • Glomerulonephritis • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Musculoskeletal Pain • Systemic Lupus Erythematosus

ANSWER-HF: sacubitril-valsartan reduces NT-proBNP in heart failure due to Chagas cardiomyopathy despite no reverse remodeling. (PubMed, Heart Fail Rev) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Amlodipine Besylate-Folic Acid demonstrates superior efficacy to Enalapril Maleate-Folic Acid in treating H-type hypertension. (PubMed, Am J Transl Res) - "Amlo-FA is effective in treating HTH."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders

COMPARATIVE EFFICACY AND SAFETY OF CARDIOPROTECTIVE DRUGS IN PREVENTING CHEMOTHERAPY-INDUCED CARDIOTOXICITY IN PEDIATRIC AND ADOLESCENT/YOUNG ADULT PATIENTS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (ACC 2026) - "Treatment groups were dexrazoxane (n=1,211), carvedilol (n=91), enalapril (n=163), atorvastatin (n=25), and placebo (n=1,447); in total, 1,490 patients received active cardioprotection. Dexrazoxane ranked highest in SUCRA analysis, significantly preserving LVEF. Overall, cardioprotective drugs were safe but showed limited impact on biomarkers or clinical outcomes in pediatric and AYA patients."

Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Pediatrics

HEART FAILURE IN AN INFANT WITH AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ACC 2026) - "Despite triple therapy with enalapril, labetalol, and amlodipine, her blood pressure remained elevated...She managed milrinone infusion for poor systolic function and nicardipine infusion for blood pressure control and later transitioned to oral medications... Cardiovascular involvement in autosomal recessive polycystic kidney disease is increasingly recognized as an early complication. The literature on ARPKD has shown that systemic hypertension and left-ventricular remodeling can occur in infancy and childhood, often before overt renal failure develops. Incorporating routine echocardiogram surveillance into standard ARPKD care may help prevent irreversible myocardial remodeling and improve long-term cardiovascular outcomes."

Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Hypertension • Nephrology • Polycystic Kidney Disease • Renal Disease

DILATED BY A DRINK: A CASE OF PPA2-RELATED CARDIOMYOPATHY (ACC 2026) - "Guideline-directed medical therapy (enalapril, spironolactone, metoprolol) was initiated for reverse remodeling, as well as a mitochondrial cocktail (CoQ10, levocarnitine, vitamin B complex) to optimize mitochondrial function. Lisinopril was avoided due to mannitol excipient... PPA2 deficiency is a rare presentation of cardiomyopathy in adolescents which can be precipitated by alcohol consumption and can be fatal if not promptly identified. Management requires multidisciplinary care including cardiology, neurology, and metabolism."

Clinical • Cardiomyopathy • Cardiovascular • Infectious Disease • Inflammation • Metabolic Disorders

DENGUE-ASSOCIATED MYOCARDITIS WITH APICAL THROMBUS IN A 28-YEAR-OLD PATIENT PROGRESSING TO HEART TRANSPLANTATION DESPITE OPTIMIZED MEDICAL THERAPY: A CASE REPORT (ACC 2026) - "Initial therapy included enalapril 10 mg BID, bisoprolol 2.5 mg daily, spironolactone 25 mg daily, and furosemide 40 mg BID...Decision-Making: Medical therapy for HFrEF was optimized with sacubitril/valsartan 100 mg BID, empagliflozin 10 mg, spironolactone 50 mg and bisoprolol 5 mg BID. Repeat echocardiography showed persistent severe dysfunction and notable apical thrombus (15 x 8 mm), and rivaroxaban 20 mg daily was initiated... Dengue-associated myocarditis, though rare, may progress to severe cardiomyopathy and advanced heart failure. This case underscores the need for vigilance in patients with dengue presenting with cardiac symptoms and highlights the role of early advanced therapy referral, including heart transplantation, when standard management fails."

Case report • Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Dengue Fever • Heart Failure • Inflammation • Pulmonary Disease • Thrombosis • Transplantation

Prevent from Home: Young person and buddies’ cardiovascuLar heaLth Improvement feasibility Study (PHYLLIS) (UKKW 2026) - "PHYLLIS will be delivered in two phases: Part A where 108 individuals, with pregnancies complicated by HdP, following informed consent will be randomised (1:1) immediately postpartum to receive enalapril or nifedipine for 16 weeks with transthoracic echocardiogram (TTE) and retinal imaging performed at baseline and final visit and Part B for 162 individuals, who have completed breastfeeding, provided informed consent and had pregnancies complicated by HdP and/or GDM who will be randomised (1:1:1) to tirzepatide, dapagliflozin or standard care for 26 weeks with a further 26 weeks of follow-up, with TTE and retinal exam performed at baseline, 26 weeks and final visit...(Ref:24/LO/0902). Preliminary results will be presented, including feasibility of a randomised study of SGLT2i and GLP-1/GIP agonists in postpartum individuals with risk factors for CVD."

Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Diabetic Retinopathy • Gestational Diabetes • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Retinal Disorders • Type 2 Diabetes Mellitus

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Region Skane | Recruiting ➔ Active, not recruiting

Enrollment closed • Complement-mediated Rare Disorders • Glomerulonephritis

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Phase classification: P4 ➔ P3 | N=7100 ➔ 10000 | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2021 ➔ Dec 2023

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=6800 | Recruiting | Sponsor: MJM Bonten | N=4000 ➔ 6800 | Trial completion date: Feb 2019 ➔ Jun 2022 | Trial primary completion date: Feb 2019 ➔ Dec 2021 | Initiation date: Dec 2015 ➔ Apr 2016

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=7100 | Recruiting | Sponsor: MJM Bonten | Trial completion date: Jun 2022 ➔ Dec 2023

Trial completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=4000 | Recruiting | Sponsor: UMC Utrecht

New P4 trial • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Trial completion date: Dec 2025 ➔ Feb 2028 | Trial primary completion date: Dec 2023 ➔ Feb 2026

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=20000 | Recruiting | Sponsor: UMC Utrecht | N=10000 ➔ 20000

Enrollment change • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

AIFA-CARDIO-129: Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (clinicaltrialsregister.eu) - P4 | N=368 | Not yet recruiting | Sponsor: Policlinico San Donato S.p.A.

New P4 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Long-term results of endovascular treatment of middle aortic syndrome in a child (clinical case) (PubMed, Angiol Sosud Khir) - "Antiplatelet therapy (acetylsalicylic acid) and antihypertensive therapy (enalapril) were prescribed. Transcatheter techniques do not always achieve complete elimination of the stenotic area and require close follow-up due to the risk of neointimal hyperplasia. Nevertheless, the endovascular approach to palliative correction of mid-aortic syndrome allows the child to reach an optimal age for definitive surgical repair while reducing the need for repeated open procedures."

Journal

Efficacy and Safety of Sacubitril/Valsartan Versus Enalapril in the Treatment of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis. (PubMed, Cureus) - "Sacubitril/valsartan demonstrates superior efficacy over enalapril in key clinical and patient-reported outcomes. Further research is needed to investigate its long-term safety and effectiveness across diverse patient populations."

Journal • Retrospective data • Review • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypotension

Effect of Sacubitril-Valsartan on Secondary Mitral Regurgitation and Left Ventricular Reverse Remodeling in Patients With Heart Failure With Reduced Ejection Fraction: A 2D and 3D Echocardiographic Study. (PubMed, Echocardiography) - "Sacubitril-valsartan (S/V), an angiotensin receptor-neprilysin inhibitor (ARNI), has demonstrated superiority over enalapril in reducing morbidity and mortality in HFrEF. The strong correlation between these two effects suggests that MR improvement is primarily driven by LVRR. Lower baseline LVEF is a powerful predictor of the magnitude of LVRR."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Efficacy and safety of sacubitril-valsartan versus enalapril in patients with heart failure due to Chagas cardiomyopathy: a systematic review and meta-analysis (HEART FAILURE 2026) - No abstract available

Retrospective data • Review • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Challenges in managing pediatric heart failure, especially in resource-limited settings. (PubMed, Ann Pediatr Cardiol) - "Notably, the recent PANORAMA-HF trial showed that sacubitril/valsartan was similarly effective to enalapril but did not achieve statistically superior outcomes in children. Furthermore, pulmonary artery banding has re-emerged as a surgical strategy to induce left ventricular recovery in young children with dilated cardiomyopathy. Given the disparity in outcomes and the reliance on extrapolated adult data, there is an urgent need for large-scale, pediatric-specific clinical trials to optimize global management strategies."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Pediatrics • Transplantation

Clinical Outcomes of Neonates Receiving Antihypertensive Treatment. (PubMed, Z Geburtshilfe Neonatol) - "Monotherapy with amlodipine, enalapril, or captopril was used in most cases, while combination therapy was required in two neonates with renal etiologies. Persistent hypertension occurs mainly in neonates with structural renal or vascular abnormalities, while those with other causes often discontinue therapy before discharge. These findings highlight the importance of identifying neonates at risk for long-term complications."

Clinical data • Journal • Acute Kidney Injury • Cardiovascular • Critical care • Genetic Disorders • Hypertension • Infectious Disease • Nephrology • Polycystic Kidney Disease • Renal Disease • Septic Shock